Quarterly Result2 Jun 2026, 12:24 pm
Wanbury FY26 PAT Surges 117% to ₹66.1 Cr; EPS Doubles to ₹20.55
AI Summary
Wanbury Limited reported strong financial performance for FY26, with revenue from operations growing 8.5% YoY to ₹650.3 crore and PAT surging 117% YoY to ₹66.1 crore. The company's EBITDA rose 34.9% to ₹107.7 crore, supported by improved product mix, procurement efficiencies, and process optimization. Despite a temporary revenue impact in Q4 FY26 due to the West Asia crisis affecting API exports, the company maintained a strong margin profile. Operational highlights include the launch of a new Anaesthetic API, successful regulatory inspections with zero observations in Korea, and the implementation of SAP HANA S4 to drive efficiency.
Key Highlights
- FY26 PAT grew 117% YoY to ₹66.1 crore with margins expanding 509 bps to 10.2%.
- EPS more than doubled to ₹20.55 in FY26 compared to ₹9.32 in the previous year.
- EBITDA increased 34.9% to ₹107.7 crore, driven by operational efficiencies and better yields.
- Company achieved zero-observation status in recent MFDS Korea, USFDA, and ANVISA Brazil regulatory inspections.
- New Anaesthetic API launched from the Tanuku facility with commercial dispatches commencing in February 2026.
Price Impact
More from WANBURY